Fig. 1: Characteristics of our patient cohort and FLT3 mutations.

A Schematic representation of FLT3 domains and their amino acid location depicting type and number of mutations, disease groups, and variant interpretation according to practice guidelines set forth by the ACMG. Double hits within the same sample are indicated by an asterisk. B Pie chart breakdown of frequency of FLT3 mutations and type of mutations. C Co-mutation analysis comparing FLT3^ITD, FLT3^AL, and FLT3^NC subgroups. D Response to phosphotyrosine kinase inhibitors in cases carrying FLT3^NC vs. FLT3^AL. E Kaplan–Meier curves showing probability of survival in cases with FLT3^AL and FLT3^NC AML subgroups divided by phosphothyrosine kinase inhibitors treatment status. Comparisons were considered statistically significant at P values less than 0.05. WT, wild type; MT, mutation; AML, acute myeloid leukemia; ITD, internal tandem duplication; AL, activation loop; NC, non-canonical; TKI, tyrosine kinase inhibitor; MDS, myelodysplastic syndrome, MPN, myeloproliferative neoplasms.